


## REVIEW

## Open Access



# Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons

Muhlis Akman<sup>1</sup>, Dimas Carolina Belisario<sup>1</sup>, Iris Chiara Salaroglio<sup>1</sup>, Joanna Kopecka<sup>1</sup>, Massimo Donadelli<sup>2</sup>, Enrico De Smaele<sup>3</sup> and Chiara Riganti<sup>1\*</sup> 

## Abstract

Solid tumors often grow in a micro-environment characterized by < 2% O<sub>2</sub> tension. This condition, together with the aberrant activation of specific oncogenic pathways, increases the amount and activity of the hypoxia-inducible factor-1α (HIF-1α), a transcription factor that controls up to 200 genes involved in neoangiogenesis, metabolic rewiring, invasion and drug resistance. Hypoxia also induces endoplasmic reticulum (ER) stress, a condition that triggers cell death, if cells are irreversibly damaged, or cell survival, if the stress is mild.

Hypoxia and chronic ER stress both induce chemoresistance. In this review we discuss the multiple and interconnected circuitries that link hypoxic environment, chronic ER stress and chemoresistance. We suggest that hypoxia and ER stress train and select the cells more adapted to survive in unfavorable conditions, by activating pleiotropic mechanisms including apoptosis inhibition, metabolic rewiring, anti-oxidant defences, drugs efflux. This adaptative process unequivocally expands clones that acquire resistance to chemotherapy.

We believe that pharmacological inhibitors of HIF-1α and modulators of ER stress, although characterized by low specificity and anti-cancer efficacy when used as single agents, may be repurposed as chemosensitizers against hypoxic and chemorefractory tumors in the next future.

**Keywords:** Hypoxia, Hypoxia-inducible factor-1α, Endoplasmic reticulum stress, Unfolded protein response, Chemoresistance

## Background: the impact of hypoxia on cancer and its microenvironment

Cancer growth is supported by the continuous interaction between transformed and non-transformed cells, including cancer-associated fibroblasts, endothelial cells and immune-infiltrating cells that constitute the so-called tumor microenvironment (TME).

Within TME, cancer cells are subjected to multiple stresses caused by shortage of oxygen (O<sub>2</sub>) and nutrients, chronic inflammation, damages induced by immune cells or exogenous factors, such as chemotherapy and radiotherapy. O<sub>2</sub> shortage is the most common condition that

tumors must face [1]. The highest O<sub>2</sub> concentration (13.2%) is measured in arterial blood and is considered as normoxia [2]. Under physiological conditions, the O<sub>2</sub> concentration in human tissues varies between 1 and 11%. Most solid tumors grow under hypoxic conditions, i.e. below 2% O<sub>2</sub> [3, 4].

When facing hypoxic conditions, cancer cells can undergo two processes: slowing their progression and ending-up in necrosis/apoptosis, or adapting to the unfavorable conditions. This adaptation expands more aggressive clones that become predominant in the tumor heterogeneous population [5]. This process is mainly orchestrated by hypoxia-inducible factors (HIFs), i.e. specific hypoxia sensors that support cell survival by inducing compensatory angiogenesis, extracellular matrix (ECM) remodelling, metabolic shift and immune-suppression [6–10].

\* Correspondence: [chiara.riganti@unito.it](mailto:chiara.riganti@unito.it)

<sup>1</sup>Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

HIF proteins are dimers consisting of an unstable, O<sub>2</sub>-sensitive  $\alpha$  subunit and a constitutively expressed, O<sub>2</sub>-insensitive  $\beta$  subunit. Three HIF $\alpha$  proteins - HIF-1 $\alpha$ , HIF-2 $\alpha$  and HIF-3 $\alpha$ , each with multiple splicing variants – and one HIF $\beta$  protein were identified in higher organisms [11]. Although HIF-1 $\alpha$  is ubiquitous and HIF-2 $\alpha$  prevails in heart and liver, both of them are expressed in many cancer types and have overlapping functions. Little is known on HIF-3 $\alpha$ , whose study is complicated by the multiple variants of this protein present in humans [12].

Under normoxia, the labile  $\alpha$  subunits are hydroxylated by the prolyl hydroxylase dioxygenase (PHD) enzymes [13], which generate a binding site for the von Hippel Lindau tumor suppressor protein (pVHL). Following the pVHL binding, HIF $\alpha$  is poly-ubiquitinated and then degraded by the proteasome [14, 15]. PHD is an O<sub>2</sub>-dependent enzyme: under hypoxic conditions, HIF $\alpha$  is not primed for ubiquitination, but it accumulates and binds to its  $\beta$  subunit, and is free to translocate into the nucleus [16, 17]. Besides hypoxia, HIF-1 $\alpha$  stabilization may be promoted by oncogenic activation of pro-survival pathways such as Ras/PI3K/Akt/mTOR [18], mutations in key oncosuppressor genes such as TP53 [19] or BRCA1/PTEN axis [20], metabolites paracrinely released in the TME such as glutamate [21]. Similarly, the intracellular accumulation of reactive oxygen species (ROS) inactivates PHD, increasing HIF-1 $\alpha$  within tumors [11].

Specific miRNAs stabilize HIF-1 $\alpha$  [22] and are involved in the hypoxia-mediated modulation of angiogenesis, apoptosis, proliferation, metastasis and chemoresistance [23]. For instance, the increase in HIF-1 $\alpha$  is associated to the up-regulation of miR-155, miR-10b, miR-372, miR-373, miR-210 and miR-519c, and to the down-regulation of miR-17-92, miR-20b, miR-200b and miR-199 [24].

HIF proteins induce up to 200 genes that promote adaptation to hypoxia [6, 11], involved in proliferation, glucose metabolism and angiogenesis in many different cancer types [25–27]. Among them, there are glucose transporter 1 (GLUT1), which increases the glucose uptake fuelling the anaerobic glycolysis, and vascular endothelial growth factor (VEGF), a well-known angiogenic factor [28]. HIF-1 $\alpha$  is a strong inducer of other glycolytic enzymes that contribute to an increased rate of anaerobic glycolysis, coupled with a lower rate of tricarboxylic acid (TCA) cycle. This phenotype is typical of several solid cancers addicted to glucose as the main fuel source [29]. In addition, HIF-1 $\alpha$  down-regulates oxidative phosphorylation (OXPHOS) by inducing the Hes-related family BHLH transcription factor with YRPW motif (HEY) repressor [30], decreases the expression of carnitine palmitoyl transferase 1A (CPT1A), the limiting-enzyme of fatty acid  $\beta$ -oxidation (FAO) [31] and inhibits the electron transport chain (ETC) [32]. As a result, both anaplerotic pathways of TCA cycle and ETC are limited. The main

benefit derived from the inhibition of mitochondrial metabolism is the decreased level of ROS and the prevention of cytotoxic oxidative stress [33].

Both HIF-1 $\alpha$  and HIF-2 $\alpha$  promote a more invasive phenotype [33], by activating the epithelial-mesenchymal transition (EMT) program [34–36] or cooperating with other strong pro-invasive factors such as Met receptor and soluble hepatocyte growth factor (HGF) [37], or VEGF receptor (VEGFR)/VEGF [38]. Notably, in triple negative breast cancer (TNBC) HIF-1 $\alpha$  stimulates the release of the typical pro-inflammatory cytokine IL-1 $\beta$  that induces a metastatic attitude in both tumor cells and cancer associated fibroblasts (CAFs), creating a TME that strongly favors metastatization [39]. In addition, HIF-1 $\alpha$  also promotes a tumor-tolerant environment, reducing the infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes and tumor-associated macrophages (TAMs) [40], increasing the differentiation of T-lymphocytes into T-helper 17 (TH17) cells [41] and modulating TAM polarization [42]. Overall, the hypoxia-driven reshaping of immune-environment is associated to increased tumor progression, particularly in the early stages [43].

Given the pleiotropic functions regulated, HIF-1 $\alpha$  expression has been used as a stratification factor. Specific signatures of HIF-1 $\alpha$ -target genes have a negative prognostic significance in hepatocellular carcinoma (HCC) [44]. Similarly, a meta-analysis focused on the prognostic role of HIF-2 $\alpha$  demonstrated that a higher expression of this transcription factor is associated with a worst overall survival, metastasis-free and progression-free survival in melanoma, breast and lung cancer [45].

Hypoxia and nutrients shortage are two classical conditions inducing endoplasmic reticulum (ER) stress, a perturbation of the ER homeostasis that determines the accumulation of unfolded or misfolded proteins within ER lumen. As hypoxia does, also ER stress may evolve into two opposite situations: the activation of pro-apoptotic program, with consequent cell death in case of acute ER stress, or the activation of pro-survival responses, in case of chronic and mild ER stress [46]. In a strict parallelism with hypoxia, also ER stress determines the selection of tumor populations with a multistress-resistant phenotype, i.e. able to survive in the presence of unfavorable and changing conditions, such as O<sub>2</sub> and nutrients shortage, or exposure to chemotherapeutic drugs [47]. Solid tumors experiment continuous changes in O<sub>2</sub> and nutrients supply. Indeed, if the hypoxia-induced neo-angiogenesis provides O<sub>2</sub> and nutrients, the neo-vessels formed easily collapse under the pressure of the growing tumor mass. This situation implies that repeated cycles of hypoxia and re-oxygenation occur within the tumor, and that normoxic and hypoxic areas coexist within the tumor bulk. The poorly organized vasculature also determines an irregular delivery of chemotherapeutic drugs. Tumors are

heterogeneous masses composed by hypoxic niches, characterized by severe shortage of O<sub>2</sub> and nutrients, and stronger ER stressing conditions, and well-oxygenated areas, less subjected to ER stress [48, 49]. In this review, we will discuss how the adaptation to hypoxia and to the hypoxia-induced ER stress contribute to the expansion of aggressive tumor clones and to the acquisition of chemoresistance, by triggering pro-survival/anti-apoptotic responses. A better knowledge of the cross-talks between hypoxia and ER stress may open new therapeutic opportunities effective against tumors refractory to classical chemotherapy, by targeting HIF activation and modulating the response to ER stress.

### The variable response to ER stress in cancer cells

In eukaryotic cells, protein folding and maturation are handled by ER, where nascent polypeptide chains synthesized by ribosomes are folded and undergo post-translational modifications, such as disulfide bonds formation and glycosylation. Synthesized proteins must pass the ER-associated protein degradation/ER-quality control (ERAD/ERQC) system, constituted by ER-associated protein complexes that deliver the properly folded proteins to their final destination, the unfolded/misfolded proteins to ubiquitination and degradation via proteasomes or autophagosomes/lysosomes [50, 51]. ERAD/ERQC proteins are often overexpressed in cancers [52], as part of an adaptive response that help cancer cells to survive in unfavorable environments. Upon glucose deprivation, oxidative stress, aging or hypoxia, ERAD/ERQC system can be overwhelmed. Unfolded proteins accumulate within the ER lumen, triggering the so-called unfolded protein response (UPR) that results in cell death or ER stress compensation and consequent survival [46, 53, 54].

When unfolded proteins accumulate, ER-resident chaperones such as glucose-regulated protein 78 (GRP78) increases the folding capacity or proceeds to the clearance of unfolded proteins via ERAD machinery. In parallel, protein translation is reduced, to limit the burden of unfolded proteins accumulated within the ER lumen [55]. If both options fail, cells initiate apoptosis [54]. Inositol-requiring enzyme-1 $\alpha$  (IRE1 $\alpha$ ), activating transcription factor-6 (ATF6) and protein kinase R-like endoplasmic reticulum kinase (PERK) are ER transmembrane proteins that act as ER-stress sensors and UPR effectors [46, 53, 54], and are activated by GRP78 [56].

IRE1 $\alpha$  activates X-box-binding protein 1 (XBP-1) that up-regulates genes increasing proteins folding, ERAD machinery and ER biogenesis [57, 58], or – if the ER stress persists – up-regulates genes involved in apoptosis, such as c-Jun N-terminal kinase 1 (JNK1) [56].

ATF6 controls the second arm of UPR. It increases the transcription of chaperones and ERAD pathway members,

as well as GRP78, generating a feed-forward loop which buffers ER stress [55].

The third sensor of UPR is PERK that - by phosphorylating on serine the eukaryotic initiating factor 2 $\alpha$  (eIF2 $\alpha$ ) - reduces the mRNA translation rate, attenuating the accumulation of misfolded proteins within ER [58, 59]. At the same time, PERK increases the translation of the activating transcription factor-4 (ATF4) that induces the transcription of chaperones, anti-oxidant enzymes and enzymes involved in aminoacid metabolism, favoring resistance to oxidative stress and drugs [56]. ATF4 indeed may promote the transcription of CCAA T/enhancer-binding protein homologous protein (CHOP) that induces apoptosis in case of prolonged stress [46, 53, 54], but also protective autophagy [60].

Multiple cross-talks between the three arms of ER stress exist. For instance, ATF6 also enhances IRE1 $\alpha$ /XBP-1 axis [61]. Together, they promote the degradation of misfolded proteins during embryonic [62] and cancer development [63]. Also PERK activates ATF6, by favoring its synthesis and translocation from ER to Golgi [64]. Interestingly, as observed for HIF-1 $\alpha$  [22, 24], miRNAs act both as controllers of expression of UPR proteins and modulators of the UPR response [65]. Only in one case, miRNA expression changes in the same direction under hypoxic conditions and ER stress: mir-17, which is down-regulated by HIF-1 $\alpha$  [24], is also reduced during ER stress. Such decrease, favored by the activation of IRE1 $\alpha$ , promotes the switch from an adaptive UPR response to a pro-apoptotic response [65]. This parallelism suggests that specific miRNAs may contribute to the effects that both HIF-1 $\alpha$  and ER stress have on the cell fate. These miRNAs may be part of the same molecular circuitries, linking the hypoxic-induced ER stress to the ER stress-induced cell death or survival. However, further analyses are needed to unveil if other miRNAs have the same modulation in case of hypoxia and ER stress, or if hypoxia-dependent and UPR-dependent miRNAs belong to two different and independent sets.

Overall, the redundancy of pathways facing ER stress, the versatility of the response observed and the circuitries influenced in the same way by hypoxia and ER stress suggest that UPR is a crucial and finely regulated mechanism controlling the cell fate in response to pleiotropic unfavorable conditions.

### Hypoxia and ER stress: a double-liaison selecting aggressive and resilient clones

Hypoxia is often a cause of ER stress, for at least two reasons: first, specific processes physiologically occurring within ER are altered in hypoxic conditions; second, HIF-1 $\alpha$  modulates the expression and activity of ER stress sensors.

Many post-translational modifications are O<sub>2</sub>-dependent, e.g. the oxidation and isomerization of cysteine thiol groups

that form disulfide bonds, or the hydroxylation of collagen on proline residues. In hypoxia, proteins are regularly synthesized but their folding is impaired and induces ER stress [66, 67]. Moreover, under hypoxic conditions, several splicing variants of common proteins are produced [68]: these variants may be sensed as abnormally folded proteins by the ERAD/ERQC apparatus, triggering a UPR response. Finally, the altered OXPHOS metabolism that is often observed under hypoxia generates ROS, which oxidize mitochondrial proteins and/or impact on their folding. This triggers a mitochondrial UPR (mUPR) that is additive to the ER-dependent UPR [69, 70].

On the other hand, HIF-1 $\alpha$  controls the activity and expression of UPR sensors. HIF-1 $\alpha$  transcriptionally up-regulates VEGF, which activates phospholipase C (PLC) and inositol-3-phosphate (IP<sub>3</sub>)-dependent calcium release: the oscillations in calcium levels trigger the activation of UPR arms [71]. Although this mechanism was reported in human endothelial cells, a similar cascade of events may occur in hypoxic cancer cells, rich of VEGFR and autocrinely producing VEGF. In addition, hypoxia increases GRP78 expression via extracellular signal-regulated kinase (ERK) and protein kinase C (PKC) [72], thus activating the *primum movens* of the three UPR arms. One mechanism explaining the hypoxia-driven increase of GRP78 relies on the cell migration-inducing and hyaluronan-binding protein (CEMIP), an ER-residing protein that is overexpressed in several solid cancers in response to hypoxia. CEMIP transcriptionally up-regulates GRP78 and binds it in the ER: the CEMIP/GRP78 complex increases glucose uptake, prevents apoptosis and promotes cell migration by raising the intracellular calcium and the activity of PKC $\alpha$  [73], thus producing a better adaptation to hypoxia.

The final results of the hypoxia-induced UPR are variable, and depend on the degree and duration of hypoxia. For instance, while HIF-1 $\alpha$  and HIF-2 $\alpha$  are activated starting from < 3% O<sub>2</sub>, when the O<sub>2</sub> tension is reduced to 0.1% the mammalian target of rapamycin (mTOR) is progressively inhibited and eIF2 $\alpha$  is phosphorylated: these two events reduce the global translation of proteins [74].

The key role of PERK/eIF2 $\alpha$  axis in pro-survival response during hypoxia has been demonstrated by the fact that cancer cells with an intact PERK/eIF2 $\alpha$  axis are more tolerant to hypoxia and more tumorigenic [75]. These findings suggest that PERK activity makes cancer cells more resilient and aggressive. Notably, the activation of PERK is HIF-1 $\alpha$ -dependent and is stronger after normoxia-hypoxia cycles, a condition often occurring within tumor bulks where the vasculature is irregular [56]. The acquisition of hypoxia-tolerance following PERK activation is mainly mediated by the downstream effector ATF4. Indeed, tumors with defective PERK/eIF2 $\alpha$ /ATF4 axis have apoptotic areas

overlapping with hypoxic areas [75], suggesting that a functioning PERK/eIF2 $\alpha$ /ATF4 is required to limit the hypoxia-induced damages. Moreover PERK/eIF2 $\alpha$  signalling buffers the increasing ROS levels observed in cyclic hypoxia, by increasing GSH and autophagy. These events have improved the survival of glioblastoma cells in response to the oxidative damages induced by oscillating hypoxia or radiotherapy [76, 77]. In human cervix cancer, the hypoxic induction of PERK/eIF2 $\alpha$ /ATF4 signalling up-regulates the pro-metastatic protein lysosomal-associated membrane protein 3 (LAMP3) [78], linking hypoxic activation of PERK to another aggressive behavior of cancer cells.

IRE1 $\alpha$ /XBP-1 and ATF6 are also up-regulated during hypoxia, although the biological meaning of their activation has been less studied. XBP-1 transcription and splicing are higher in hypoxic tumors [79]. Like PERK, also IRE1 $\alpha$  modulates autophagy in response to hypoxia [80], mounting a cytoprotective response. The use of selective inhibitors of PERK and IRE1 $\alpha$ , however, clarified that the blocking of IRE1 $\alpha$  and XBP-1 splicing did not reduce cell proliferation during hypoxia, contrarily to the inhibition of PERK [81]. These observations suggest a predominant role of PERK/eIF2 $\alpha$  axis over IRE1 $\alpha$ /XBP-1 axis in hypoxia tolerance and tumor growth.

If it is well documented that hypoxia induces ER stress, it is also true that ER stress sensors increase HIF-1 $\alpha$  activity and hypoxia-related events. Indeed, UPR signalling potentiates the response to hypoxia by phosphorylating and activating HIF-1 $\alpha$ , and by stabilizing VEGF protein via the up-regulation of multiple chaperones [82]. Also ATF4 and IRE1 $\alpha$  are transcriptional activators of VEGF in hypoxic cells, where they cooperate with HIF-1 $\alpha$  [83]. Such crosstalk between hypoxia and UPR is not limited to specific genes, but it is part of a more generalized response: in hypoxic TNBC, XBP-1 enhances the transcription of HIF-1 $\alpha$ -target genes by directly interacting with HIF-1 $\alpha$  and recruiting the RNA polymerase II on specific promoters. This XBP1-HIF-1 $\alpha$ -dependent signature is associated with tumor aggressiveness and poor prognosis [84].

Sometimes UPR- and hypoxia-driven responses do not act in the same direction. Depending on the temporal order of the events (i.e. UPR preceding hypoxia or hypoxia determining UPR), on the severity and duration of hypoxia or ER stress, there can be contrasting responses. For instance, upon strong ER stress, ATF4, activated by p38 mitogen activated kinase (MAPK), down-regulates apelin, an anti-apoptotic protein, which is up-regulated by HIF-1 $\alpha$  [85]: this is a typical case where the induction of strong ER stress before the up-regulation of HIF-1 $\alpha$  induces cell death, preventing the typical anti-apoptotic response mediated by HIF-1 $\alpha$ . In a complementary situation, if hypoxia triggers a strong ER stress, ROS/p38

MAPK axis, activated by HIF-1 $\alpha$ , elicits a pro-apoptotic response mediated by ATF4 [86], instead of a proliferative response as expected upon the usual activation of MAPK proteins. Similarly, in breast cancer cells HIF-1 $\alpha$  induces immediately VEGF that favors neo-angiogenesis and cell survival, but prolonged hypoxia activates the IRE $\alpha$ /XBP-1 axis that induces miR-153, a negative regulator of HIF-1 $\alpha$  [87]. Once the acute hypoxic insult is over and a chronic hypoxic environment persists, cells switch off the pro-survival programs driven by HIF-1 $\alpha$  and switch on pro-apoptotic programs. A two-phases response is observed in prostate cancer (PC) and breast cancer cells, as well as in osteosarcoma exposed to 1% O<sub>2</sub> tension: after an initial up-regulation of HIF-1 $\alpha$ , the protein is gradually reduced notwithstanding the persistence of hypoxic conditions. Indeed, after 2–3 h of hypoxia, a strong UPR is mounted, characterized by the activation of PERK that destabilizes HIF-1 $\alpha$  mRNA by disrupting its interaction with the stabilizing protein YB-1 [88]. In this case, the pro-survival programs induced by HIF-1 $\alpha$  are attenuated and the pro-apoptotic programs controlled by UPR determines cell death.

Beside the duration and extent of hypoxia or ER stress, the presence of specific oncogenic pathways is another factor that may direct hypoxia- and UPR-dependent programs towards antagonistic directions. For example, in colon cancer the hyper-activated WNT/ $\beta$ -catenin axis disrupts the interaction between XBP-1 and HIF-1 $\alpha$ , attenuating the transcriptional activity of HIF-1 $\alpha$  and decreasing the adaptation to hypoxia [89]. This response is in contrast with what observed in TNBC, where – in the absence of non-oncogenically active  $\beta$ -catenin –, XBP-1 and HIF-1 $\alpha$  cooperate in up-regulating a common set of target genes [84].

These prototypical examples suggest that HIF-1 $\alpha$ - and UPR-driven pathways can be linked by synergistic or antagonistic cross-talks, depending on duration, degree and timing of hypoxia and ER stress. Adaptation to hypoxia and UPR are dynamic processes. Hence, static measures cannot be conclusive because they do not follow the evolution of hypoxic insults and the cellular compensatory responses. Time-lapse approaches provide significantly more information on the temporal and molecular hierarchy of HIF-1 $\alpha$ - and UPR-dependent events, unveiling the cause-effect relations existing in each situation.

Given the high heterogeneity of TME in terms of O<sub>2</sub> and nutrients supply, cancer cells must continuously adapt to conditions that change spatially and temporally. If the process fails, pro-apoptotic pathways prevail and cells are eliminated. If the process is successful, this continuous adaptation promotes cell survival and tumor progression. The first scenario sensitizes cells to the damages exerted by radiotherapy and chemotherapy; the second scenario is unequivocally associated to therapy-resistance (Fig. 1).


## Hypoxia and altered UPR: two partners in crime of chemoresistance

### Hypoxia drives the acquisition of chemoresistance

In vitro, hypoxia has been reported to induce resistance to several anti-cancer drugs, including Vinka alkaloids, anthracyclines, cisplatin, etoposide, actinomycin-D, 5-fluorouracil, gemcitabine, methotrexate, in different solid cancers [90].

Both HIF-1 $\alpha$ -dependent and independent mechanisms are responsible for the chemoresistance related to hypoxia. It is well documented that hypoxic tumors have a poor vascularization that limits drug bioavailability [91]. In addition, the low O<sub>2</sub> tension reduces the possibility of inducing oxidative stress that is often a mechanism of killing exerted by chemotherapeutic drugs [36], such as cisplatin [92], doxorubicin, etoposide [93], gemcitabine [94]. Moreover, by creating an unfavorable environment, hypoxia selects aggressive and metastatic clones, as well as clones rich of anti-apoptotic proteins such as IAP3 and Bcl-2: this selection is independent on HIF-1 $\alpha$  activation [95], but it contributes to counteract the apoptosis induced by anti-cancer agents.

Most frequently, the ample transcriptional program induced by HIF-1 $\alpha$  is the main responsible for the simultaneous resistance to drugs unrelated for structures and mechanisms of action (Fig. 2). Among the main target of HIF-1 $\alpha$  there is *mdr1* gene, which encodes for P-glycoprotein/ATP binding cassette transporter B1 (Pgp/ABC B1) [96]. This protein effluxes many chemotherapeutic drugs, contributing to tumor multidrug resistance (MDR) [97]. In vitro 3D-models mimic well the chemoresistance observed in the hypoxic core of solid tumors: both hormone-dependent and TNBC 3D models display a significant activation of HIF-1 $\alpha$ , coupled with an increased Pgp up-regulation and resistance to doxorubicin, compared to parental 2D-cultured doxorubicin-sensitive cells [98, 99]. The reversion of doxorubicin resistance and the down-regulation of Pgp after HIF-1 $\alpha$  inhibition with 3-(5'-hydroxymethyl-2'-furyl)-1-benzimidazole or HIF-1 $\alpha$  shRNA, prove the molecular linkage between hypoxia and HIF-1 $\alpha$ -driven Pgp expression [98]. Notably, chemoresistant tumors often have activated HIF-1 $\alpha$  in normoxia, as a result of the activation of Ras/ERK1/2 and RhoA/RhoA kinase axes that phosphorylate and stabilize HIF-1 $\alpha$ . This kind of HIF-1 $\alpha$  activity was detected in colon cancer, malignant pleural mesothelioma, non-small cell lung cancer (NSCLC), TNBC and chronic lymphatic leukemia cells [100–104]. This series of studies highlights that HIF-1 $\alpha$  alone is sufficient to induce a MDR phenotype by increasing the expression of Pgp, independently of hypoxia. In line with this observation, the oncogenic-driven activation of HIF-1 $\alpha$  is as strong as the hypoxic TME in determining chemoresistance. Hence, we may hypothesize that HIF-1 $\alpha$ -dependent chemoresistance occurs both in hypoxic




tumor areas and in well-oxygenated ones characterized by a hypoxia-independent activation of HIF-1α. These two scenarios are not antagonistic, but can co-exist, as in the case of multiple myeloma (MM): growing in an hypoxic niche in bone marrow, MM has a canonical activation of HIF-1α that induces chemoresistance, but also the concurrent activation of oncogenic pathways (e.g. Wnt, Notch, Ras/MAPK-, PI3K, Akt/mTOR-, NF-κB-dependent pathways) that prevent the apoptosis induced by chemotherapeutic drugs [90, 105].

Other MDR-related transporters are under the transcriptional control of HIF-1α, such as MDR related protein 1/ABC transporter C1 (MRP1/ABCC1) and lung resistance protein (LRP) [106]. Breast cancer resistance protein/ABC transporter G2 (BCRP/ABCG2) is up-regulated by both HIF-1α [107], which is phosphorylated and stabilized by ERK1/2 [108], and HIF-2α [109]. The simultaneous up-regulation of different transporters enormously enlarges the spectrum of drugs that lose efficacy in hypoxia or in tumors with a constitutively active HIF-1α.

An additional tumor-intrinsic mechanism linking hypoxia to chemoresistance involves the HIF-1α-driven inhibition of TP53. Both HIF-1α and HIF-2α suppress TP53-mediated apoptosis. This activity has been linked to the resistance to 5-fluorouracil in TP53 wild-type gastric cancers, but not in TP53-disrupted ones [110]. Notably, on the one hand HIF-1α destabilizes TP53, on the other hand the binding of TP53 to HIF-1α impairs the hypoxia-driven transcriptional program [111]: depending on the mutational status of TP53 and/or on the amount of HIF-1α, the interaction between these two partners may produce pro-survival effects or cell death. These two extremities oscillate from chemoresistance in the first case to chemosensitivity in the second case.

HIF-1α also prevents DNA double strand breaks, e.g. by up-regulating topoisomerase 2A. This mechanism confers resistance to etoposide in TNBC and PC [112]. This observation leads to the use of dual HIF/topoisomerase inhibitors (such as acriflavine) as potential anticancer and chemosensitizer agents [113]. At the same time,



HIF-1 $\alpha$  increases the expression of DNA repair machinery, such as DNA-PKs, Ku80 and Ku70 [114]: this mechanism, which contributes to the adaptation and survival in conditions of chronic hypoxia [115], also protects from DNA-damaging chemotherapeutic drugs.

The metabolic rewiring driven by hypoxia also plays a role in chemoresistance [116]. The huge production of lactate due to the increase in glycolysis determines a strong acidification of the TME that limits the efficacy of weak bases such as anthracyclines: indeed, these drugs are easily protonated and sequestered within lysosomes [117]. In the attempt of counteracting the strong acidification, cancer cells up-regulate carbonic anhydrase (CA) IX and XII, both under the transcriptional control of HIF-1 $\alpha$  [118, 119]. Also this event, however, is functional to induce chemoresistance. Indeed, CAXII interacts with Pgp and stimulates its activity, by creating a slightly alkaline pH in the membrane domains where the protein operates [119], and granting the maximal efficiency of the pump [120].

By down-regulating OXPHOS [30] and inducing mitophagy [121, 122], HIF-1 $\alpha$  favors chemoresistance by multiple and interconnected mechanisms. Chemotherapeutic drugs as 5-fluorouracil and cisplatin increase ROS generation [110]. The lower levels of OXPHOS detected in hypoxic cells or in cells with high levels of HIF-1 $\alpha$  may explain the lower generation of ROS and the reduced oxidative damages induced by chemotherapy in these conditions [123]. Moreover, the reductive catabolism of glutamine – i.e. the cytosolic transformation of glutamine into citrate – is a hallmark of hypoxic tumors [124]. This pathway produces NADPH, providing additional ROS-buffering agents that limit the oxidative damages elicited by chemotherapy. Of note, ROS are also necessary to stabilize TP53 and trigger apoptosis [110]: therein, HIF-1 $\alpha$ -positive cells have a lower pro-apoptotic activity of TP53 in response to chemotherapeutic drugs as cisplatin [125]. HIF-2 $\alpha$  exerts a similar contribution by decreasing intracellular ROS and limiting the stability of TP53 [110], thus providing an additional loop that induces resistance to

oxidative stress and chemotherapy. Mitophagy allows cancer cells to recover ATP, redox metabolites and building blocks, that can be used to re-synthesize biomolecules damaged by chemotherapeutic drugs, providing an additional mechanism by which the altered mitochondrial metabolism induced by HIF-1 $\alpha$  determines chemoresistance. For instance, HIF-1 $\alpha$  triggers a protective mitophagic response and at the same time confers resistance to 5-fluorouracil [126], gemcitabine [94] and cisplatin in ovarian cancer [123]. Indeed the increased rate of mitophagy [121, 122], favored by the up-regulation of the mitophagic Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (BNIP3) by HIF-1 $\alpha$  [127], compensates the lower ATP produced by OXPHOS. ATP is a necessary substrate for ABC transporters and favors the efflux of multiple chemotherapeutic drugs.

HIF-1 $\alpha$  is also a strong inducer of glutaminolysis [128] that can be reduced into citrate and generate NADPH [124], or can fuel the TCA cycle. This anaplerotic pathway, together with the reshaping of mitochondrial cristae that maximizes the ATP synthesis [129] and the increased mitobiogenesis caused by the up-regulation of the peroxisome proliferator-activated receptor gamma coactivator-1 $\alpha$  (PGC-1 $\alpha$ ) observed in hypoxic and acidic tumors [130], compensate the attenuated TCA cycle and OXPHOS induced by hypoxia.

This metabolic phenotype allows hypoxic cancer cells to rely mainly on a glycolytic metabolism, but to switch toward a mitochondrial metabolism when glucose is low. This plasticity ensures a high adaptability to the metabolic changing conditions of the TME, granting the possibility of supplying energy and building blocks by rewiring the metabolism. As a consequence, hypoxic cells are less susceptible to the oxidative and energetic damages produced by chemotherapy.

Other chemoresistance inducers that can be up-regulated by HIF-1 $\alpha$  are Pim kinases members [131] which phosphorylate and activate Pgp [132]. Also the NF- $\kappa$ B and Akt/mTOR axes, which are increased in hypoxia, may activate Pim kinases [121], amplifying chemoresistance. Collectively, Pim kinases have been implicated in resistance to cisplatin, doxorubicin and gemcitabine in pancreatic adenocarcinoma (PDAC) cells, and to docetaxel in PC cells [132, 133]. Interestingly, also specific miRNAs associated with HIF-1 $\alpha$  up-regulation are involved in chemoresistance. For instance, the HIF-1 $\alpha$ /mir-210 axis determines resistance to temozolomide in glioblastoma by increasing the cell proliferation and the acquisition of a stemness phenotype [134]. In keeping with these results, mir-210 is considered a biomarker predictive of chemoresistance in patients with metastatic breast cancer [135]. Mir-519c up-regulates ABCG2 [136], a gene target of HIF-1 $\alpha$  [107], providing an explanation for the ABCG2-mediated chemoresistance detected in tumors

with high expression of HIF-1 $\alpha$ . mir-10b confers resistance to 5-fluorouracil in colorectal cancer, where it inhibits the pro-apoptotic BH3-only Bcl-2 family member BIM (BCL2L11) and is considered a negative prognostic factor in chemotherapy-treated patients [137]. Similarly, miR-155, which determines chemoresistance in solid and hematological tumors [138], is considered a negative prognostic marker in breast cancers [139]. The correlation between high HIF-1 $\alpha$ , high levels of miRNAs dependent on HIF-1 $\alpha$  and chemoresistance, however, is not univocal. Indeed, mir-372 is a predictor of chemosensitivity in colorectal cancer [140] and mir-373 chemosensitizes gastric cancer cells [141], although they are both increased by HIF-1 $\alpha$  [24]. These data suggest that many other factors can intervene to determine if a specific miRNA induced by hypoxia causes chemoresistance or not.

Senescence is another process often associated with drug resistance [142] and sustained by HIF-1 $\alpha$ , both in normoxia [110] and hypoxia [143]. Hypoxic cells are often quiescent or slowly cycling [91, 144]. These types of cells are the most difficult to eradicate and the most resistant to drugs interfering with cell cycle, such as pemetrexed and raltitrexed [145]. By contrast, the sensitivity towards drugs acting in a cell cycle-independent manner, such as proteasome inhibitors, is preserved [145].

Finally, HIF-1 $\alpha$  increases resistance to chemotherapy by promoting EMT [36], which induces cell proliferation and migration, as demonstrated by the down-regulation of E-cadherin and the up-regulation of vimentin in hypoxic PC cells. Propofol, recently identified as a HIF-1 $\alpha$  inhibitor, not only reduces EMT but also sensitizes cells to docetaxel [146]. This mechanism is not drug- or tumor-type specific, because it is elicited also by the natural product tanshinone IIA, another HIF-1 $\alpha$  inhibitor that impairs EMT and alleviates the hypoxia-induced resistance to doxorubicin in breast cancer cells [147].

In general, hypoxic tumors display multiple and redundant mechanisms of resistance to chemotherapy. Some molecular circuitries involved in chemoresistance are part of the adaptation strategies to hypoxia or unfavorable conditions. If we consider chemotherapy as one unfavorable condition that cancer cells encounter, we might hypothesize that cells adapted to survive in hypoxia should be more prone to survive under the selective pressure of chemotherapy. An accurate choice of the type of chemotherapeutic drugs, together with the combination of HIF-1 $\alpha$  inhibitors, may ameliorate the response of hypoxic tumors to chemotherapy.

#### **An altered UPR impacts on sensitivity to chemotherapy**

Few evidences reported that ER stress induces chemosensitivity, as in the case of ovarian cancer cells and cisplatin [148], or gastric cancer and doxorubicin/vincristine [149], but in both cases the higher chemosensitivity seems independent from the resistance to ER



stress. Since under ER stressing conditions cells are depleted of ATP if they cannot recover it via autophagy, they activate a UPR-dependent apoptosis. At the same time, the low levels of ATP deprive Pgp and other ABC transporters of the energetic substrate for pumping out chemotherapeutic drugs. These mechanisms may explain why Pgp-expressing ovarian cancer cells subjected to ER stress are sensitized to paclitaxel [150].

Most often, however, an increased resistance to ER stress, as it occurs in cells adapted to survive in a hypoxic environment, determines chemoresistance.

For instance, glucose deprivation activates GRP78 that in turn increases *mdr1* gene transcription via *c/Jun* [151] and mounts a cytoprotective autophagic reaction in response to bortezomib in MM [152] or to vemurafemib in resistant BRAF<sup>V600E</sup> mutated melanoma cells [153]. On the contrary, betulinic acid-induced activation of GRP78 increases PERK/CHOP axis, promoting the apoptosis induced by taxol [154]. In accordance, the down-regulation of GRP78, coupled with the up-regulation of IRE1 $\alpha$ , is associated with resistance to cisplatin in NSCLC cells [155]. Also GRP78 downstream effectors may induce chemoresistance. In PDAC cells, PERK induces chemoresistance by phosphorylating eIF2 $\alpha$  that attenuates protein translation and prevents the accumulation of unfolded proteins within ER lumen, thus alleviating the proteostatic stress. At the same time PERK activates ATF4/CHOP axis that - contrarily to most cell types where CHOP is a proapoptotic factor [156] - exerts anti-apoptotic effects and induces resistance to gemcitabine [157]. The resistance to gemcitabine in PDAC stem cells has been also linked to the down-regulation of IRE1 $\alpha$  and the simultaneous activation of PERK, that in turn up-regulate the urokinase plasminogen activator (uPA). uPA prevents the mitochondria-dependent apoptosis elicited by gemcitabine [158], thus promoting chemoresistance by activating a cross talk between ER and mitochondria. Defective ATF6 and XBP-1 determine resistance to bortezomib in MM, coupled with reduced ER lumen and reduced ability to mount a UPR-triggered cell death in response to proteostatic stress [159]. Accordingly, the block of E1-ubiquitin-activating enzyme and the consequent proteostatic stress increase the expression of IRE1 $\alpha$ , PERK and ATF6 that cooperate in inducing apoptosis and increasing sensitivity to proteasome inhibitors, doxorubicin, melphalan and lenalidomide [160].

As it occurs for the chemoresistance associated with HIF-1 $\alpha$ , the presence of oncogenic drivers pushes the activation of specific ER stress sensors that induce chemoresistance. For instance, in chronic myeloid leukemia cells the BCR/ABL oncogene determines the constitutive phosphorylation of PERK and eIF2 $\alpha$  that prevent the ER stress-dependent apoptosis in response to imatinib, as demonstrated by the re-sensitization to the drug when PERK/eIF2 $\alpha$  activity is prevented [161]. In colon cancer,

breast cancer and osteosarcoma, PERK determines resistance to oxaliplatin and doxorubicin, via the activation of erythroid-derived 2-like 2 (Nrf2), which up-regulates anti-oxidant enzymes and MRP1 [99], two actors in the chemoresistant phenotype.

In a strict parallelism with the linkage between hypoxia and chemoresistance, also the linkage between resistance to ER stress and resistance to chemotherapy is reciprocal. On the one hand, cells selected to survive under mild and chronic ER stress conditions acquire drug resistance by up-regulating PERK, similarly to cells selected in medium with increasing concentrations of chemotherapeutic drugs that acquire a MDR phenotype [95]. On the other hand, cells with a MDR phenotype are also resistant to ER stress induced-cell death: both ER stressors and chemotherapeutic drugs - such as doxorubicin, oxaliplatin/cisplatin, 5-fluorouracil - increase the CCAAT/enhancer-binding protein- $\beta$  (C/EBP- $\beta$ ) LIP isoform that prevents the CHOP/caspase 3-mediated apoptosis and at the same time up-regulates Pgp [162]. Another linkage between ER stress adaptation/resistance and chemoresistance is provided by the observation that chemoresistant tumors often exhibit a defective ERAD/ERQC, making them constantly subjected to a chronic proteostatic stress. The adaptation to this chronic stressing condition constitutively activates ER-dependent pro-survival pathways that contribute to chemoresistance [163, 164]. However, perturbing the unstable balance between defective ERAD/ERQC system and compensatory up-regulation of pro-survival pathways may hit ER stress-resistant/chemoresistant cells in their Achilles' heel. Indeed, inducing ER stress with ER-targeting doxorubicin perturbing disulfide bonds of proteins [164] or Ag-nanoparticles inducing ER stress [165] restore chemosensitivity. The mechanism is double. First, the accumulation of misfolded proteins induces their ubiquitination and the engulfment of proteasome/autophagosome system. Second, Pgp is folded within ER and stabilized by disulfide bonds: the interference with these processes promotes its degradation, with consequent decreased efflux of chemotherapeutic drugs and sensitization to Pgp substrates [164-166].


Overall, the different stimuli that specifically activate one or more UPR arms, the different nature and timing of ER stressing conditions, the different pattern of UPR downstream transducers explain why the mechanisms linking ER stress and chemoresistance are multiple and sometimes contrasting in different tumors. This variable scenario is further complicated in the core of solid tumors, because hypoxia is a cause of both ER stress and chemoresistance, and may trigger additional circuitries increasing at the same time the resistance to ER stressing conditions and to chemotherapeutic drugs. For these reasons, hypoxic tumors should be considered characterized by a "multi-resistant" phenotype.

### The crosstalk between hypoxia and UPR-dependent circuitries induces chemoresistance

Being two hallmarks of resiliency in cancers, hypoxia and altered UPR response can cooperate in inducing chemoresistance. Multiple crosstalks exist between the pro-survival pathways activated by HIF-1 $\alpha$  and UPR (Fig. 3), and they can be enhanced by additional pro-oncogenic conditions, such as mutated TP53 [167].

Hypoxia increases the expression of GRP78 that in turn promotes an adaptive UPR response to the hypoxic environment: peculiar events in this adaptation are the down-regulation of CHOP and Bax, and the up-regulation of Bcl-2. The increased Bcl-2/Bax ratio results in the inhibition of apoptosis; in this way, the hypoxic-

driven up-regulation of GRP78 triggers resistance to cisplatin [168]. Accordingly, GRP78-silencing restores chemosensitivity, rewiring the pattern of CHOP/Bax/Bcl-2 expression, notwithstanding the persistence of an hypoxic environment [168]. GRP78 [151], as well as HIF-1 $\alpha$  [96], are transcriptional inducers of *mdr1*. Therefore, hypoxia inevitably leads to resistance towards the multiple chemotherapeutic drugs transported by Pgp. The accumulation of GRP78 and prolyl 4-hydroxylase, beta polypeptide (P4HB) in the ER lumen of hypoxic glioblastoma cells maintains low the activity of IRE1 $\alpha$  and PERK/CHOP. Hypoxia not only restores the relative levels of PERK/CHOP and IRE1 $\alpha$ , by reducing GRP78 and P4HB, but it also enhances the apoptosis



induced by temozolomide [169]. Although temozolomide mainly induces cell death by alkylating DNA, in an ER-independent way, the sensitization to the drug cytotoxicity is likely due to the induction of “two apoptotic hits”, the first one at the DNA level, the second one at the ER level, as suggested by the synergism achieved by hyperoxia and temozolomide.

PERK/eIF2 $\alpha$ /ATF4 axis is typically induced by hypoxia [56] and contributes to the hypoxia-induced chemoresistance with multiple mechanisms. First, PERK increases the phosphorylation and activity of the anti-apoptotic forkhead box O-1 (FOXO-1), together with pro-autophagic factors [170]. The inhibition of apoptosis and the increased autophagy concurrently protect cells from chemotherapeutic drugs. Again, UPR-dependent and hypoxia-dependent axes synergize, because HIF-1 $\alpha$  induces FOXO-1 transcription [171], promotes protective autophagy [172] and activates PERK/eIF2 $\alpha$ /ATF4 axis [56]. By cooperating with HIF-1 $\alpha$  in up-regulating MMP9 [173], PERK and HIF-1 $\alpha$  also promote migration, helping cancer cells to leave unfavorable environments and escape from cytotoxic agents. As mentioned above, Nrf2 is also activated by PERK and confers chemoresistance by up-regulating MRP1 [99] and anti-oxidant enzymes [170]. Of note, hypoxia-associated ROS up-regulate both HIF-1 $\alpha$  and Nrf2: the sum of their transcriptional programs unequivocally worsens chemoresistance [174].

IRE1 $\alpha$ /XBP-1 [79] and ATF6 [175] are activated in hypoxic cells as well, although the role of such increase in chemoresistance is not univocal. While the increase of ATF6 and the decrease of IRE1 $\alpha$  has been linked to resistance to cisplatin in NSCLC [155], in MM the low activity of both ATF6 and IRE-1 $\alpha$  induces resistance to bortezomib [159]. By contrast, XBP-1 up-regulation determines a more aggressive phenotype in TNBC. In this tumor, XBP-1 gene signature is strongly associated with HIF-1 $\alpha$  gene signature, and they correlate with a lower relapse-free survival [84]. Since chemotherapy is the first treatment option for TNBC, the high HIF-1 $\alpha$ /high XBP-1 phenotype could be indicative of poor response to chemotherapeutic drugs and consequent lower survival.

In addition, hypoxic niches are enriched of cancer stem cells (CSCs) that are usually chemoresistant [176], because they have higher expression of ABC transporters [177, 178] and HIF-1 $\alpha$ -mediated up-regulation of MMP9, C-X-C chemokine receptor type 4 (CXCR4), osteopontin, IL-8 and VEGF [179] that promote invasion and chemoresistance. In addition, CSCs may show a differential UPR response than differentiated cells [180]. For instance, cervical CSCs show high resistance to the ER stress cell death induced by tunicamycin, because they down-regulate pro-apoptotic pathways dependent from IRE1 $\alpha$  and activate pro-survival pathways


dependent from PERK. This shift also induces cisplatin resistance that can be reversed by specific inhibitors of IRE1 $\alpha$  and PERK [180]. Colon CSCs have down-regulated specific mediators of ER stress-dependent cell death (such as CHOP) and are more resistant to chemotherapy with oxaliplatin, 5-fluorouracil and irinotecan. Inducing ER stress with subtilase cytotoxin A, that cleaves and activates GRP78, promotes chemosensitization and loss of stemness phenotype [181]. Paradoxically, chemotherapeutic drugs that induce a pro-apoptotic UPR in differentiated cells, such as gemcitabine, activate pro-survival and pro-invasive pathways dependent on ATF6 in PDAC CSCs [158]. These findings suggest that the acquisition of stemness properties, driven by the growth in hypoxic environment, induces an altered UPR that mediates chemoresistance.

The experimental evidences reported above clearly indicate that the mechanisms linking UPR, hypoxia and chemoresistance are multiple and often tumor-specific. Being the results of an adaptive program to unfavorable conditions, these mechanisms must be considered in a dynamic perspective. Depending on the degree of hypoxia, timing and exposure to chemotherapeutic drugs, the same molecular axis can be turned-on or turned-off, activating opposite and compensatory pathways that lead to cell death or survival.

## Conclusions and future perspectives

In solid tumors the hypoxic microenvironment determines a continuous ER stress. Like in the aphorism “What does not kill me, makes me stronger”, the combined pressure of two unfavourable conditions eliminates the most sensitive cells, but it trains the most resistant cells to survive and mount a network of adaptive responses to environmental stresses. This ability is plastic and determines the progressive acquisition of multiple resistances, e.g. resistance to oxidative stress, to nutrient shortage, to chemotherapy. As a result of this selective pressure, the most chemoresistant and aggressive clones emerge during tumor progression. Since hypoxia induces pro-survival UPR-dependent pathways and chemoresistance, and an altered UPR mediates chemoresistance both in normoxia and hypoxia, disrupting these vicious circles may help in finding new chemosensitizing strategies or drug combinations inducing synthetic lethality (Fig. 4).

Several UPR activators (e.g. GRP78 activator perillyl alcohol, ATF6 activator  $\Delta$ 9-tetrahydrocannabinol) or inhibitors (e.g. GRP78 blocker epigallochetchin gallate, ATF6 blocker ceapins, IRE1- $\alpha$  inhibitors salicylaldehyde-derivatives, PERK inhibitors GSK2606414 and GSK2656157) have been employed as inducers of apoptosis in cancer preclinical models [182–184], but only few of them have reached clinical trials (<https://clinicaltrials.gov/ct2/results?term=drug+>



targeting+UPR). The multiple crosstalks, as well as the involvement of UPR in several physiologic processes in non-transformed tissues, make it difficult to have safe and effective therapeutic strategies at the present. For instance, GSK2656157 is a direct inhibitor of PERK: since PERK is a key actor in the hypoxia-mediated chemoresistance, it has been administered in PDAC xenografts that are notoriously refractory to the majority of treatments [185]. Although GSK2656157 successfully reduced tumor growth, decreased vessel density and altered aminoacid metabolism, it also damaged pancreatic  $\beta$ -cells [185]. Therefore, the risk of insulin resistance or diabetes discouraged from using GSK2656157 in patients. To limit the damages on normal tissues, hypoxia-activated PERK inhibitor prodrugs have been produced, by using a 2-nitroimidazole moiety that is enzymatically reduced in hypoxic conditions into the active drug. The first tests in colon cancer cells were promising, although these prodrugs effectively inhibited PERK only in the micromolar range [186]. At this concentration, the risk of off-target effects is high, raising questions on the feasibility of this approach in patients.

Also, HIF-1 $\alpha$  targeting is complicated because of the multiple pathways that control HIF-1 $\alpha$  expression and of the multiple transcriptional programs that are controlled by HIF-1 $\alpha$ . Inhibitors of HIF-1 $\alpha$  translation (EZN-29-68, PX-478, Vorinostat, digoxin), stability (PX-478, Vorinostat, YC-1) and transcriptional activity (YC-1, acriflavine), or inhibitors of HIF-1 $\alpha$  upstream inducers, as PI3K/Akt/mTOR axis, are the most used drugs at the present [187, 188]. Some of these compounds have shown good chemosensitizing effects. In several preclinical models of solid and hematologic tumors, direct inhibitors of HIF-1 $\alpha$ , such as YC-1 [103] and BAY87-2243 [189], or indirect down-

regulators of HIF-1 $\alpha$  signalling, as the anti-androgen dutasteride [190], the alkaloid emetine [191], the lncRNA HITT [192] – one of the multiple ncRNA that regulate HIF-1 $\alpha$  [193] –, have induced chemosensitization, by reducing HIF-1 $\alpha$  transcriptional activity. The disadvantage of these inhibitors is their aspecificity. In order to overcome this limitation, the first liposomal formulations containing acriflavine co-encapsulated with doxorubicin have been produced, and demonstrated a superior tumor targeting and anti-tumor efficacy than doxorubicin alone [173]. Currently, more than 100 trials are testing HIF-1 $\alpha$  inhibitors as anti-cancer agents (<https://clinicaltrials.gov/ct2/results/details?cond=Cancer&term=HIF>), despite the results were below the expectations. A partial explanation of this failure is that HIF-1 $\alpha$  is a hallmark of aggressive and resistant cancers. Indeed, HIF-1 $\alpha$  presence is a synonymous of cells characterized by multiple and redundant resistance pathways: the inhibition of HIF-1 $\alpha$  can only partially turn-off their pro-survival attitude.

Pharmacological interventions on multiple pathways can achieve better results. In this perspective, the simultaneous targeting of UPR and HIF-1 $\alpha$  can be considered a valid approach. For instance, geldanamycin, a HSP90 inhibitor, induces at the same time ER stress and HIF-1 $\alpha$  ubiquitination, down-regulating its angiogenic transcriptional program [194]. Bortezomib and nelfinavir, two drugs able to elicit ER stress by inducing a proteostatic stress [159, 195], also down-regulate HIF-1 $\alpha$  activity [196, 197]. These few examples highlight that the dual targeting of UPR and HIF-1 $\alpha$  with FDA-approved drugs is feasible. This drug-repurposing strategy can be exploited as a new chemosensitizing approach, although problematic toxicities in patients cannot be excluded also in this case.

Although not translatable to patients in the present, the pharmacological and mechanistic studies on the cross-talk between hypoxia, UPR and chemoresistance, are useful to put together the pieces of the puzzle linking these three players. Increasing our understanding on these circuitries will steer the pharmacological research towards more precise and effective approaches to counteract hypoxic and chemoresistant tumors in the next future.

#### Abbreviations

ATF4: activating transcription factor-4 (ATF4); ATF6: activating transcription factor-6; BCRP/ABCG2: breast cancer resistance protein/ATP binding cassette transporter G2; CAFs: cancer associated fibroblasts; C/EBP- $\beta$  LIP: CCAAT/enhancer-binding protein- $\beta$  LIP; CEMIP: cell migration-inducing and hyaluronan-binding protein; CHOP: CCAAT/Enhancer-binding protein homologous protein; CPT1A: carnitine palmitoyl transferase 1A; ECM: extracellular matrix; eIF2 $\alpha$ : eukaryotic initiating factor 2 $\alpha$ ; EMT: epithelial-mesenchymal transition; ER: endoplasmic reticulum; ERAD/ERQC: ER-associated protein degradation/ER-quality control system; ERK: extracellular signal-regulated kinase; ETC: electron transport chain; FAO: fatty acid  $\beta$ -oxidation; FOXO-1: forkhead box O-1; GLUT1: glucose transporter 1; GRP78: glucose-regulated protein 78; HCC: hepatocellular carcinoma; HEY: Hes-related family BHLH transcription factor with YRPW motif repressor; HGF: hepatocyte growth factor; HIF: hypoxia-inducible factor; IRE1 $\alpha$ : inositol-requiring enzyme-1 $\alpha$ ; JNK1: c-Jun N-terminal kinase; LAMP: lysosomal-associated membrane protein 3; LRP: lung resistance protein; MAPK: p38 mitogen activated kinase; MDR: multidrug resistance; MM: multiple myeloma; MMP9: matrix metalloproteinase 9; MRP1/ABCC1: multidrug resistance related protein 1/ATP binding cassette transporter C1; mTOR: mammalian target of rapamycin; mUPR: mitochondrial unfolded protein response; Nrf2: nuclear factor erythroid-derived 2-like 2; NSCLC: non-small cell lung cancer; O<sub>2</sub>: oxygen; OXPHOS: oxidative phosphorylation; PC: prostate cancer; PDAC: pancreatic adenocarcinoma; PERK: protein kinase R-like endoplasmic reticulum kinase; Pgp/ABCB1: P-glycoprotein/ATP binding cassette transporter B1; PHDs: prolyl hydroxylase dioxygenase enzymes; PKC: protein kinase C; PLC: phospholipase C; pVHL: von Hippel Lindau tumor suppressor protein; ROS: reactive oxygen species; TAM: tumor-associated macrophage; TCA: tricarboxylic acid cycle; TH17: T-helper 17 cells; TME: tumor microenvironment; TNBC: triple negative breast cancer; TOPA2A: topoisomerase 2A; uPA: urokinase plasminogen activator; UPR: unfolded protein response; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; XBP-1: X-box-binding protein 1

#### Acknowledgments

We are grateful to Prof. Amalia Bosia, Department of Oncology, University of Torino, for the fruitful discussion.

#### Authors' contributions

MA, DCB, ICS and JK prepared the first draft of the manuscript (sections 1 and 3: MA; sections 2 and 4: DCB, ICS and JK); MD, EDS and CR: revised the draft and wrote section 5; CR: supervised the work. All authors read and approved the final manuscript.

#### Funding

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC; IG21408 to CR).

#### Availability of data and materials

Not applicable.

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. <sup>2</sup>Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Verona, Italy. <sup>3</sup>Department of Experimental Medicine, Sapienza University of Roma, Roma, Italy.

Received: 13 November 2020 Accepted: 28 December 2020

Published online: 11 January 2021

#### References

1. Finley LWS, Thompson CB, Mendelsohn J, Gray JW, Howley PM, Israel MA. 13 - The Metabolism of Cell Growth and Proliferation. *The Molecular Basis of Cancer* (Fourth Edition). Philadelphia: Content Repository Only; 2015. p. 191–208.e2.
2. Ivanovic Z, Vlaski-Lafarge M. 2 - In Situ Normoxia versus "Hypoxia". *Anaerobiosis and Stemness*. Boston: Academic Press; 2016. p. 17–21.
3. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. *Br J Radiol*. 2014;87:20130676.
4. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. *Hypoxia (Auckl)*. 2015;3:83–92.
5. Suh DH, Kim HS, Kim B, Song YS. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. *Biochem Pharmacol*. 2014;92:43–54.
6. Semenza GL. Hypoxia-inducible factors in physiology and medicine. *Cell*. 2012;148:399–408.
7. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. *Cancer Metab*. 2014;2:3.
8. Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. *Int J Cancer*. 2016;138:1058–66.
9. Samanta D, Semenza GL. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. *Biochim Biophys Acta Rev Cancer*. 2018;1870:15–22.
10. Moldogazieva NT, Mokhosoev IM, Terentiev AA. Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK. *Cancers (Basel)*. 2020;12:862.
11. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell*. 2008;30:393–402.
12. Duan C. Hypoxia-inducible factor 3 biology: complexities and emerging themes. *Am J Physiol Cell Physiol*. 2016;310:C260–9.
13. Semenza GL. HIF-1, O<sub>2</sub>, and the 3 PHDs: How Animal Cells Signal Hypoxia to the Nucleus. *Cell*. 2001;107:1–3.
14. Kaelin WG. The von Hippel-Lindau tumour suppressor protein: O<sub>2</sub> sensing and cancer. *Nat Rev Cancer*. 2008;8:865–73.
15. Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. *Semin Cancer Biol*. 2013;23:18–25.
16. Kaelin WG. The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. *Trans Am Clin Climatol Assoc*. 2017;128:298–307.
17. Pugh CW, Ratcliffe PJ. New horizons in hypoxia signaling pathways. *Exp Cell Res*. 2017;356:116–21.
18. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J Clin Invest*. 2013;123:3664–71.
19. Sethi N, Kikuchi O, McFarland J, Zhang Y, Chung M, Kafker N, et al. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. *JCI Insight*. 2019;4:128439.
20. Li AG, Murphy EC, Culhane AC, Powell E, Wang H, Bronson RT, et al. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 $\alpha$  activation. *Proc Natl Acad Sci USA*. 2018;115:E9600–E9.
21. Briggs KJ, Koivunen P, Cao S, Backus KM, Olenchock BA, Patel H, et al. Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. *Cell*. 2016;166:126–39.
22. Serocki M, Bartoszewski S, Janaszak-Jasiecka A, Ochocka RJ, Collawn JF, Bartoszewski R. miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. *Angiogenesis*. 2018;21:183–202.
23. Shen G, Li X, Jia YF, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. *Acta Pharmacol Sin*. 2013;34:336–41.
24. Pocock R. Decoding the microRNA response to hypoxia. *Pflugers Arch*. 2011; 461:307–15.

25. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1 $\alpha$  versus HIF-2 $\alpha$  in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. *Cancer Res.* 2006;66:6264–70.
26. Keith B, Johnson RS, Simon MC. HIF1 $\alpha$  and HIF2 $\alpha$ : sibling rivalry in hypoxic tumour growth and progression. *Nat Rev Cancer.* 2011;12:9–22.
27. Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. *Trends Cancer.* 2016;2:758–70.
28. Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. *J Exp Clin Cancer Res.* 2020;39:204.
29. He G, Jiang Y, Zhang B, Wu G. The effect of HIF-1 $\alpha$  on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. *Asia Pac J Clin Nutr.* 2014;23:174–80.
30. Kung-Chun Chiu D, Pui-Wah Tse A, Law CT, Ming-Jing Xu I, Lee D, Chen M, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. *Cell Death Dis.* 2019;10:934.
31. Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. *Nat Commun.* 2017;8:1769.
32. Okamoto A, Sumi C, Tanaka H, Kusunoki M, Iwai T, Nishi K, et al. HIF-1-mediated suppression of mitochondrial electron transport chain function confers resistance to lidocaine-induced cell death. *Sci Rep.* 2017;7:3816.
33. Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. *Future Oncol.* 2013;9:1623–36.
34. Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1 $\alpha$ -ZEB1 axis. *Cancer Lett.* 2015;359:107–16.
35. Yang J, Zhang X, Zhang Y, Zhu D, Zhang L, Li Y, et al. HIF-2 $\alpha$  promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. *J Exp Clin Cancer Res.* 2016;35:26.
36. Liu J, Gao L, Zhan N, Xu P, Yang J, Yuan F, et al. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. *J Exp Clin Cancer Res.* 2020;39:137.
37. Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. *Proc Natl Acad Sci USA.* 2014;111:13373–8.
38. Wang X, Che X, Yu Y, Cheng Y, Bai M, Yang Z, et al. Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin  $\alpha$ 5-fibronectin pathway. *J Exp Clin Cancer Res.* 2020;39:221.
39. Lappano R, Talia M, Cirillo F, Rigracciolo DC, Scordamaglia D, Guzzi R, et al. The IL1 $\beta$ -IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). *J Exp Clin Cancer Res.* 2020;39:153.
40. Serganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, et al. LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. *PLoS One.* 2018;13:e0203965.
41. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell.* 2011;146(5):772–84.
42. Lee KE, Simon MC. SnapShot: Hypoxia-Inducible Factors. *Cell.* 2015;163:1288 e1.
43. Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B. Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. *J Transl Med.* 2016;14:85.
44. Deng F, Chen D, Wei X, Lu S, Luo X, He J, et al. Development and validation of a prognostic classifier based on HIF-1 signaling for hepatocellular carcinoma. *Aging (Albany NY).* 2020;12:3431–50.
45. Moreno Roig E, Yaromina A, Houben R, Groot AJ, Dubois L, Vooijs M. Prognostic Role of Hypoxia-Inducible Factor-2 $\alpha$  Tumor Cell Expression in Cancer Patients: A Meta-Analysis. *Front Oncol.* 2018;8:224.
46. Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. *Cancer Discov.* 2015;5:586–97.
47. Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance. *Biol Cell.* 2019;111:1–17.
48. Rovida E, Peppicelli S, Bono S, Bianchini F, Tusa I, Cheloni G, et al. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. *Cell Cycle.* 2014;13:3169–75.
49. Cheloni G, Poteti M, Bono S, Masala E, Mazure NM, Rovida E, et al. The Leukemic Stem Cell Niche: Adaptation to "Hypoxia" versus Oncogene Addiction. *Stem Cells Int.* 2017;2017:4979474.
50. Printsev I, Curiel D, Carraway KL. Membrane Protein Quantity Control at the Endoplasmic Reticulum. *J Membr Biol.* 2017;250:379–92.
51. Hano M, Tomášová L, Šereš M, Pavlíková L, Breier A, Sulová Z. Interplay between P-Glycoprotein Expression and Resistance to Endoplasmic Reticulum Stressors. *Molecules.* 2018;23:337.
52. Nagelkerke A, Bussink J, Sweep FC, Span PN. The unfolded protein response as a target for cancer therapy. *Biochim Biophys Acta.* 2014;1846:277–84.
53. Oakes SA. Endoplasmic Reticulum Stress Signaling in Cancer Cells. *Am J Pathol.* 2020;190:934–46.
54. Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. *Nat Rev Mol Cell Biol.* 2020;21:421–38.
55. Schröder M, Kaufman RJ. ER stress and the unfolded protein response. *Mutat Res.* 2005;569:29–63.
56. Bartoszewska S, Collawn JF. Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia. *Cell Mol Biol Lett.* 2020;25:18.
57. Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science.* 2006;313:104–7.
58. Adames TR, Rondeau NC, Kabir MT, Johnston BA, Truong H, Snow JW. The IRE1 pathway regulates honey bee Unfolded Protein Response gene expression. *Insect Biochem Mol Biol.* 2020;121:103368.
59. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature.* 1999;397:271–4.
60. B'chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, et al. The eIF2 $\alpha$ /ATF4 pathway is essential for stress-induced autophagy gene expression. *Nucleic Acids Res.* 2013;41:7683–99.
61. Yamamoto K, Sato T, Matsui T, Sato M, Okada T, Yoshida H, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6 $\alpha$  and XBP1. *Dev Cell.* 2007;13:365–76.
62. Iwawaki T, Akai R, Yamanaka S, Kohno K. Function of IRE1  $\alpha$  in the placenta is essential for placental development and embryonic viability. *Proc Natl Acad Sci USA.* 2009;106:16657–62.
63. Hillary RF, FitzGerald U. A lifetime of stress: ATF6 in development and homeostasis. *J Biomed Sci.* 2018;25:48.
64. Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, et al. The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. *Mol Biol Cell.* 2011;22:4390–405.
65. Upton JP, Wang L, Han D, Wang ES, Huskey NE, Lim L, et al. IRE1 $\alpha$  cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. *Science.* 2012;338:818–22.
66. Bentovim L, Amarilio R, Zelzer E. HIF1 $\alpha$  is a central regulator of collagen hydroxylation and secretion under hypoxia during bone development. *Development.* 2012;139:4473–83.
67. Koritzinsky M, Levitin F, van den Beucken T, Rumantir RA, Harding NJ, Chu KC, et al. Two phases of disulfide bond formation have differing requirements for oxygen. *J Cell Biol.* 2013;203:615–27.
68. Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. *J Exp Clin Cancer Res.* 2020;39:110.
69. Melber A, Haynes CM. UPR<sup>mt</sup> regulation and output: a stress response mediated by mitochondrial-nuclear communication. *Cell Res.* 2018;28:281–95.
70. Shpilka T, Haynes CM. The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. *Nat Rev Mol Cell Biol.* 2018;19:109–20.
71. Karali E, Bellou S, Stellas D, Klinakis A, Murphy C, Fotsis T. VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. *Mol Cell.* 2014;54:559–72.
72. Song MS, Park YK, Lee JH, Park K. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C- $\epsilon$ /ERK/AP-1 signaling cascade. *Cancer Res.* 2001;61:8322–30.
73. Banach A, Jiang YP, Roth E, Kuscu C, Cao J, Lin RZ. CEMIP upregulates BIP to promote breast cancer cell survival in hypoxia. *Oncotarget.* 2019;10:4307–20.
74. Koumenis C, Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. *Mol Cancer Res.* 2006;4:423–36.

75. Fels DR, Koumenis C. The PERK/eIF2 $\alpha$ /ATF4 module of the UPR in hypoxia resistance and tumor growth. *Cancer Biol Ther*. 2006;5:723–8.
76. Rouschop KM, Dubois LJ, Keulers TG, van den Beucken T, Lambin P, Bussink J, et al. PERK/eIF2 $\alpha$  signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. *Proc Natl Acad Sci USA*. 2013;110:4622–7.
77. Mudassar F, Shen H, O'Neill G, Hau E. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. *J Exp Clin Cancer Res*. 2020;39:208.
78. Mujcic H, Nagelkerke A, Rouschop KM, Chung S, Chaudary N, Span PN, et al. Hypoxic activation of the PERK/eIF2 $\alpha$  arm of the unfolded protein response promotes metastasis through induction of LAMP3. *Clin Cancer Res*. 2013;19:6126–37.
79. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. *Cancer Res*. 2004;64:5943–7.
80. Chipurupalli S, Kannan E, Tergaonkar V, D'Andrea R, Robinson N. Hypoxia Induced ER Stress Response as an Adaptive Mechanism in Cancer. *Int J Mol Sci*. 2019;20:749.
81. Cojocari D, Vellanki RN, Sit B, Uehling D, Koritzinsky M, Wouters BG. New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1 $\alpha$  signaling is essential for promoting adaptation and survival to hypoxia. *Radiother Oncol*. 2013;108:541–7.
82. Pereira ER, Frudd K, Awad W, Hendershot LM. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). *J Biol Chem*. 2014;289:3352–64.
83. Drogat B, Auguste P, Nguyen DT, Boucheccareilh M, Pineau R, Nalbantoglu J, et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. *Cancer Res*. 2007;67:6700–7.
84. Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatzia Apostolou M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1 $\alpha$  pathway. *Nature*. 2014;508:103–7.
85. Jeong K, Oh Y, Kim SJ, Kim H, Park KC, Kim SS, et al. Apelin is transcriptionally regulated by ER stress-induced ATF4 expression via a p38 MAPK-dependent pathway. *Apoptosis*. 2014;19:1399–410.
86. Kwon SJ, Song JJ, Lee YJ. Signal pathway of hypoxia-inducible factor-1 $\alpha$  phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells. *Clin Cancer Res*. 2005;11:7607–13.
87. Liang H, Xiao J, Zhou Z, Wu J, Ge F, Li Z, et al. Hypoxia induces miR-153 through the IRE1 $\alpha$ -XBP1 pathway to fine tune the HIF1 $\alpha$ /VEGFA axis in breast cancer angiogenesis. *Oncogene*. 2018;37:1961–75.
88. Ivanova IG, Park CV, Yemm AJ, Kenneth NS. PERK/eIF2 $\alpha$  signaling inhibits HIF-induced gene expression during the unfolded protein response via YB1-dependent regulation of HIF1 $\alpha$  translation. *Nucleic Acids Res*. 2018;46:3878–90.
89. Xia Z, Wu S, Wei X, Liao Y, Yi P, Liu Y, et al. Hypoxic ER stress suppresses  $\beta$ -catenin expression and promotes cooperation between the transcription factors XBP1 and HIF1 $\alpha$  for cell survival. *J Biol Chem*. 2019;294:13811–21.
90. Doktorova H, Hrabeta J, Khalil MA, Eckschlager T. Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2015;159:166–77.
91. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. *Drug Resist Updat*. 2011;14:191–201.
92. Zhang W, Xiong H, Pang J, Su Z, Lai L, Lin H, et al. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production. *Toxicol Lett*. 2020;331:1–10.
93. Sinha BK. Role of Oxygen and Nitrogen Radicals in the Mechanism of Anticancer Drug Cytotoxicity. *J Cancer Sci Ther*. 2020;12:10–8.
94. Wang L, Bi R, Yin H, Liu H, Li L. ENO1 silencing impairs hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells. *Am J Transl Res*. 2019;11:4470–80.
95. Coffey RN, Morrissey C, Taylor CT, Fitzpatrick JM, Watson RW. Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1  $\alpha$  mediated in prostate carcinoma cells. *Cancer*. 2005;103:1363–74.
96. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Res*. 2002;62:3387–94.
97. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer*. 2002;2:48–58.
98. Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. *BMC Cancer*. 2012;12:4.
99. Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, et al. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. *Mol Cancer*. 2017;16:91.
100. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. *PLoS One*. 2013; e60975:8.
101. Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, et al. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. *Oncotarget*. 2015;6:1128–42.
102. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, et al. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. *Oncotarget*. 2015;6:31461–78.
103. Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, et al. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. *Oncotarget*. 2015;6:29833–46.
104. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzón-Daza ML, et al. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. *Oncotarget*. 2016; 7:20753–72.
105. Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. *Oncotarget*. 2013;4: 2186–207.
106. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX. Involvement of hypoxia-inducible factor-1 $\alpha$  in multidrug resistance induced by hypoxia in HepG2 cells. *J Exp Clin Cancer Res*. 2005;24:565–74.
107. Nishihashi K, Kawashima K, Nomura T, Urakami-Takebayashi Y, Miyazaki M, Takano M, et al. Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2. *Biol Pharm Bull*. 2017;40:82–7.
108. He X, Wang J, Wei W, Shi M, Xin B, Zhang T, et al. Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1 $\alpha$  and contributes to chemoresistance in pancreatic cancer cells. *Cancer Biol Ther*. 2016;17:188–98.
109. He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y, et al. Hypoxia-inducible factor-2 $\alpha$  directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. *Mol Oncol*. 2019;13:403–21.
110. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, et al. Hypoxia-inducible factor 1 $\alpha$  determines gastric cancer chemosensitivity via modulation of p53 and NF- $\kappa$ B. *PLoS One*. 2010; e12038:5.
111. Obacz J, Pastorekova S, Vojtesek B, Hrstka R. Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. *Mol Cancer*. 2013;12:93.
112. Sullivan R, Graham CH. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. *Mol Cancer Ther*. 2009;8:1702–13.
113. Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, et al. Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. *Oncotarget*. 2016;7:3341–56.
114. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1  $\alpha$ -deficient mouse embryonic fibroblasts. *Carcinogenesis*. 2008;29:2306–16.
115. Bouquet F, Ousset M, Biard D, Fallone F, Dauvillier S, Frit P, et al. A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia. *J Cell Sci*. 2011;124(Pt 11): 1943–1951.
116. Belisario DC, Kopecka J, Pasino M, Akman M, De Smaele E, Donadelli M, Riganti C. Hypoxia Dictates Metabolic Rewiring of Tumors. Implications for Chemoresistance. *Cells*. 2020;9:E2598.

117. Guo B, Tam A, Santi SA, Parissenti AM. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. *BMC Cancer*. 2016;16:762.
118. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. *Cancer Res*. 2009;69:358–68.
119. Kopecka J, Campia I, Jacobs A, Frei AP, Ghigo D, Wollscheid B, et al. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. *Oncotarget*. 2015;6:6776–93.
120. Aänismaa P, Seelig A. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells. *Biochemistry*. 2007;46:3394–404.
121. Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, et al. Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. *Cancer Res*. 2019;79:5218–32.
122. Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. *Drug Resist Updat*. 2019;46:100643.
123. Mai L, Luo M, Wu JJ, Yang JH, Hong LY. The combination therapy of HIF1 $\alpha$  inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells. *Neoplasma*. 2019;66:776–84.
124. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature*. 2011;481:380–4.
125. Hao J, Song X, Song B, Liu Y, Wei L, Wang X, et al. Effects of lentivirus-mediated HIF-1 $\alpha$  knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. *Cancer Gene Ther*. 2008;15:449–55.
126. Liu L, Sun L, Zhang H, Li Z, Ning X, Shi Y, et al. Hypoxia-mediated up-regulation of MGR1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. *Int J Cancer*. 2009;124:1707–15.
127. Zhu X, Chen HH, Gao CY, Zhang XX, Jiang JX, Zhang Y, et al. Energy metabolism in cancer stem cells. *World J. Stem Cells*. 2020;12:448–61.
128. Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, et al. VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. *Cancer Discov*. 2017;7:1284–305.
129. Khacho M, Tarabay M, Patten D, Khacho P, MacLaurin JG, Guadagno J, et al. Acidosis overrides oxygen deprivation to maintain mitochondrial function and cell survival. *Nat. Commun*. 2014;5:3550.
130. Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, et al. Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. *Oncogene*. 2019;38:5339–55.
131. Warfel NA, Sainz AG, Song JH, Kraft AS. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. *Mol Cancer Ther*. 2016;15:1637–47.
132. Isaac M, Siu A, Jongstra J. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. *Drug Resist Updat*. 2011;14:203–11.
133. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. *Mol Cancer Res*. 2005;3:443–51.
134. Wang P, Yan Q, Liao B, Zhao L, Xiong S, Wang J, et al. The HIF1 $\alpha$ /HIF2 $\alpha$ -miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions. *Cell Death Dis*. 2020;11:992.
135. Shao B, Wang X, Zhang L, Li D, Liu X, Song G, et al. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. *Technol Cancer Res Treat*. 2019;18:1533033819828709.
136. To KK, Leung WW, Ng SS. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. *Exp Cell Res*. 2015;338:222–31.
137. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. *Ann Surg Oncol*. 2012;19:3065–71.
138. Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. *Cancer Metastasis Rev*. 2018;37:33–44.
139. Bahrami A, Aledavoud A, Anvari K, Hassanian SM, Maftouh M, Yaghoobzade A, et al. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. *J Cell Physiol*. 2018;233:774–86.
140. Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. *Anticancer Drugs*. 2014;25:346–52.
141. Wei B, Sun X, Geng Z, Shi M, Chen L, et al. Isoproterenol regulates CD44 expression in gastric cancer cells through STAT3/MicroRNA373 cascade. *Biomaterials*. 2016;105:89–101.
142. Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, et al. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. *Cancer Res*. 2020;80:890–900.
143. Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. *Mol Cancer Ther*. 2008;7:1961–73.
144. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. *Nat Rev Cancer*. 2011;11:393–410.
145. Raz S, Sheban D, Gonen N, Stark M, Berman B, Assaraf YG. Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest. *Cell Death Dis*. 2014;5:e1067.
146. Qian J, Shen S, Chen W, Chen N. Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1. *Biomed Res Int*. 2018;2018:4174232.
147. Fu P, Du F, Chen W, Yao M, Lv K, Liu Y. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1 $\alpha$  downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. *Oncol Rep*. 2014;31:2561–8.
148. Yamada M, Tomida A, Yun J, Cai B, Yoshikawa H, Taketani Y, et al. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. *Cancer Chemother Pharmacol*. 1999;44:59–64.
149. Wu J, Chen S, Liu H, Zhang Z, Ni Z, Chen J, et al. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. *J Exp Clin Cancer Res*. 2018;37(1):272.
150. Zheng X, Andruska N, Lambrecht MJ, He S, Parissenti A, Hergenrother PJ, et al. Targeting multidrug-resistant ovarian cancer through estrogen receptor  $\alpha$  dependent ATP depletion caused by hyperactivation of the unfolded protein response. *Oncotarget*. 2018;9:14741–53.
151. Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. *Cancer Res*. 2003;63:7284–90.
152. Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, et al. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. *Oncotarget*. 2015;6:3098–110.
153. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. *J Clin Invest*. 2014;124:1406–17.
154. Cai Y, Zheng Y, Gu J, Wang S, Wang N, Yang B, et al. Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78. *Cell Death Dis*. 2018;9:636.
155. Tufo G, Jones AW, Wang Z, Hamelin J, Tajeddine N, Esposti DD, et al. The protein disulfide isomerases PDI4 and PDI6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. *Cell Death Differ*. 2014;21:685–95.
156. Hu H, Tian M, Ding C, Yu S. The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection. *Front Immunol*. 2018;9:3083.
157. Palam LR, Gore J, Craven KE, Wilson JL, Korc M. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. *Cell Death Dis*. 2015;6:e1913.
158. Wang L, Zhang Y, Wang W, Zhu Y, Chen Y, Tian B. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). *PLoS One*. 2017;12:e0184110.
159. Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. *Clin Transl Immunology*. 2018;7:e1007.



160. Zhuang J, Shirazi F, Singh RK, Kuitatse I, Wang H, Lee HC, et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. *Blood*. 2019;133:1572–84.
161. Kusio-Kobialka M, Podrzywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, et al. The PERK-eIF2 $\alpha$  phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. *Cell Cycle*. 2012;11:4069–78.
162. Riganti C, Kopecka J, Panada E, Barak S, Rubinstein M. The role of C/EBP- $\beta$  LIP in multidrug resistance. *J Natl Cancer Inst*. 2015;107:djv046.
163. Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. *Blood*. 2016;127:1896–906.
164. Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, et al. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. *Cell Mol Life Sci*. 2019;76:609–25.
165. Gopisetty MK, Kovács D, Igaz N, Rónavári A, Béteky P, Rázga Z, et al. Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells. *J Nanobiotechnology*. 2019;17:9.
166. Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, et al. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. *Cancer Lett*. 2019;456:29–39.
167. D'Orazi G, Cirone M. Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression. *Cancers (Basel)*. 2019;11:614.
168. Pi L, Li X, Song Q, Shen Y, Lu X, Di B. Knockdown of glucose-regulated protein 78 abrogates chemoresistance of hypopharyngeal carcinoma cells to cisplatin induced by unfolded protein in response to severe hypoxia. *Oncol Lett*. 2014;7:685–92.
169. Lee D, Sun S, Ho AS, Kiang KM, Zhang XQ, Xu FF, et al. Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. *Anticancer Res*. 2014;34:2957–66.
170. Bu Y, Diehl JA. PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. *J Cell Physiol*. 2016;231:2088–96.
171. Sun W, Wang B, Qu XL, Zheng BQ, Huang WD, Sun ZW, et al. Metabolism of Reactive Oxygen Species in Osteosarcoma and Potential Treatment Applications. *Cells*. 2019;9:87.
172. Xia Y, Jiang L, Zhong T. The role of HIF-1 $\alpha$  in chemo-/radioresistant tumors. *Onco Targets Ther*. 2018;11:3003–11.
173. Xu L, Zhang Z, Ding Y, Wang L, Cheng Y, Meng L, et al. Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species. *Biomater Sci*. 2019;7:4782–9.
174. Toth RK, Warfel NA. Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia. *Antioxidants (Basel)*. 2017;6:27.
175. Tang JY, Jin P, He Q, Lu LH, Ma JP, Gao WL, et al. Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1 $\alpha$  and PERK signaling activation. *Mol Cell Biochem*. 2017;424:111–22.
176. Kabakov A, Yakimova A, Matchuk O. Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy. *Cells*. 2020;9:892.
177. Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/ $\beta$ -catenin pathway. *Neuro. Oncol*. 2013;15:1502–17.
178. Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, et al. Wnt/IL-1 $\beta$ /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. *Int J Cancer*. 2020;146:192–207.
179. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene*. 2010;29:4741–51.
180. Fujimoto A, Kawana K, Taguchi A, Adachi K, Sato M, Nakamura H, et al. Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. *Oncotarget*. 2016;7:51854–64.
181. MCB W, Colak S, Heijmans J, van Lidth de Jeude JF, Rodermond HM, et al. ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy. *Cell Rep*. 2015;13:489–94.
182. Hetz C, Axten JM, Patterson JB. Pharmacological targeting of the unfolded protein response for disease intervention. *Nat Chem Biol*. 2019;15:764–75.
183. Markouli M, Strepkos D, Papavassiliou AG, Piperi C. Targeting of endoplasmic reticulum (ER) stress in gliomas. *Pharmacol Res*. 2020;157:104823.
184. Martelli AM, Paganelli F, Chiarini F, Evangelisti C, McCubrey JA. The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. *Cancers (Basel)*. 2020;12:333.
185. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. *Cancer Res*. 2013;73:1993–2002.
186. Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay MP. Hypoxia-Activated Prodrugs of PERK Inhibitors. *Chem Asian J*. 2019;14:1238–48.
187. Fallah J, Rini BI. HIF Inhibitors: Status of Current Clinical Development. *Curr Oncol Rep*. 2019;21:6.
188. Semenza GL. Pharmacologic Targeting of Hypoxia-Inducible Factors. *Annu Rev Pharmacol Toxicol*. 2019;59:379–403.
189. Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, et al. HIF-1 $\alpha$  is over-expressed in leukemic cells from. *Haematologica*. 2020;105:1042–54.
190. von Wahlde MK, Hülsewig C, Ruckert C, Götte M, Kiesel L, Bernemann C. The anti-androgen drug dutasteride renders triplex negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1 $\alpha$ -/VEGF-signaling. *Gynecol Endocrinol*. 2015;31:160–4.
191. Cornet-Masana JM, Moreno-Martínez D, Lara-Castillo MC, Nomdedeu M, Etxabe A, Tesi N, et al. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. *Oncotarget*. 2016;7:23239–50.
192. Zhao K, Wang X, Xue X, Li L, Hu Y. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. *PLoS Biol*. 2020;18:e3000666.
193. Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. The interplay between HIF-1 $\alpha$  and noncoding RNAs in cancer. *J Exp Clin Cancer Res*. 2020;39:27.
194. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. *J Biol Chem*. 2002;277:29936–44.
195. De Gassart A, Bujisic B, Zaffalon L, Decosterd LA, Di Micco A, Frera G, et al. An inhibitor of HIV-1 protease modulates constitutive eIF2 $\alpha$  dephosphorylation to trigger a specific integrated stress response. *Proc Natl Acad Sci USA*. 2016;113:E117–26.
196. Abd-Aziz N, Stanbridge EJ, Shafee N. Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. *Oncol Lett*. 2015;10:2192–6.
197. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. *Cancer Res*. 2006;66:9252–9.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

